.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Cipla
Cerilliant
Covington
Medtronic
Harvard Business School
Boehringer Ingelheim
Novartis
Julphar
US Department of Justice

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090702

« Back to Dashboard
NDA 090702 describes LITHIUM CARBONATE, which is a drug marketed by Hetero Labs Ltd Iii, Watson Labs, West-ward Pharms Int, Hikma Intl Pharms, Glenmark Generics, Mylan Pharms Inc, Able, Sun Pharm Inds Inc, Heritage Pharma, Pfizer, Usl Pharma, Glenmark Pharms Inc, Alembic Pharms Ltd, Alembic Ltd, Unique Pharm Labs, Barr, and Apotex Inc, and is included in twenty-nine NDAs. It is available from thirty-three suppliers. Additional details are available on the LITHIUM CARBONATE profile page.

The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.

Summary for 090702

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 090702

Medical Subject Heading (MeSH) Categories for 090702

Suppliers and Packaging for NDA: 090702

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LITHIUM CARBONATE
lithium carbonate
CAPSULE;ORAL 090702 ANDA Camber Pharmaceuticals Inc. 31722-544 31722-544-01 100 CAPSULE in 1 BOTTLE (31722-544-01)
LITHIUM CARBONATE
lithium carbonate
CAPSULE;ORAL 090702 ANDA Camber Pharmaceuticals Inc. 31722-544 31722-544-05 500 CAPSULE in 1 BOTTLE (31722-544-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength150MG
Approval Date:Sep 25, 2009TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength300MG
Approval Date:Sep 25, 2009TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength600MG
Approval Date:Sep 25, 2009TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
McKesson
Healthtrust
Fish and Richardson
Teva
QuintilesIMS
Chubb
Queensland Health
Colorcon
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot